hVIVO (LON:HVO) Stock Price Down 46.3% - Should You Sell?

hVIVO plc (LON:HVO - Get Free Report)'s share price was down 46.3% on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares were traded during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a report on Friday.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock's 50-day simple moving average is GBX 16.16 and its two-hundred day simple moving average is GBX 18.13. The stock has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,459.93). Company insiders own 14.03% of the company's stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.